<DOC>
	<DOCNO>NCT00864435</DOCNO>
	<brief_summary>To compare rate extent absorption carvedilol test formulation Carvedilol 12.5 mg Tablets versus reference Coreg® 12.5 mg Tablets fast condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Carvedilol 12.5 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Two-way crossover , randomize , open-label , single-dose , fasting , bioequivalence study Official Title : A Two-Way Crossover , Open-Label , Single Dose , Fasting , Bioequivalence Study Carvedilol 12.5 mg Tablets Versus Coreg® 12.5 mg Tablets Normal , Healthy , Non-Smoking Male Female Subjects Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>1 . Nonsmoking male female minimum age 18 year . 2 . Body Mass Index ( BMI = weight/heigh2 ) great equal 18.5 kg/m2 less equal 29.9 kg/m2 3 . Normal finding physical examination , 12lead ECG vital sign ( blood pressure 106140/6690 mmHg , heart rate 6099 beats/minute , temperature 35.8°C 37.5°C ) 4 . Negative drug abuse nicotine . 5 . Negative hepatitis Bsurface antigen , hepatitis C HIV . 6 . Female subject : negative pregnancy ( evaluate serum ßCG test ) . 7 . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator decide clinically significant . 8 . Female subject surgically sterile least 6 month postmenopausal least 1 year , avoid pregnancy least 10 day study , study 1 month end study . 9 . Availability subject entire study period willingness subject adhere protocol requirement , evidence sign ICF 1 . Known history hypersensitivity carvedilol ( e.g . Coreg® ) and/or related beta¬blockers propranolol ( Inderal® , nadolol ( Corgard® ) , labetalol ( Trandate® , metoprolol ( Lopressor® , Betaloc® , atenolol ( Tenormin® , sotalol , timolol , pindolol , acebutolol . 2 . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , liver kidney disease , unless deem clinically significant Principal Investigator Subinvestigator . 3 . Presence significant physical organ abnormality . 4 . Any history evidence psychiatric psychological disease ( include depression ) unless deem clinically significant Principal Investigator Subinvestigator . 5 . Known history frequent headache migraine . 6 . Known history chronic bronchitis bronchospastic condition . 7 . Any clinically significant illness 4 week study . 8 . Known history presence food allergy , condition know interfere absorption , distribution , metabolism excretion drug . 9 . Any history severe allergic reaction ( include drug , food , insect bite , environmental allergen ) . 10 . Significant recent history asthma ( 12 year age ) . 11 . Any subject history drug abuse . 12 . Any subject recent ( less 1 year ) history alcohol abuse . 13 . Use prescription medication within 14 day precede study . 14 . Use overthecounter ( OTC ) cough cold medication contain dextromethorphan within 14 day precede study . 15 . Use OTC medication within 7 day precede study ( except spermicidal/barrier contraceptive product ) . 16 . Female subject : use contraceptive ( oral , emergency [ plan B® , transdermal , implant , Mirena® IUD , NuvaRing® ) within 30 day drug administration depot injection progestogen drug ( e.g . DepoProvera® within 1 year drug administration . 17 . Female subject : evidence pregnancy lactation . 18 . Any subject blood drawn within 56 day precede study , conduct clinical study facility BCR , within lockout period specify previous study conduct BCR . 19 . Participated clinical trial investigational drug within 30 day precede study . 20 . Any subject donate blood within 56 day precede study . 21 . Any subject participate plasma donor plasmapheresis program within 7 day precede study . 22 . Intolerance venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Carvedilol</keyword>
	<keyword>Healthy subject</keyword>
</DOC>